4890.T
Tsubota Laboratory Incorporated
グロース · 医薬品 · 医薬品 · JP
JPY 300.00
+1.69%Aug 13, 2026, 04:26 UTC
Tsubota Laboratory announced that the Phase 2a trial of TLM-001, an ophthalmic drug for meibomian gland dysfunction licensed to Maruho, achieved Last Patient Out on June 25, 2026.
Source:Aug 13, 2026, 04:26 UTC
Tsubota Laboratory announced that it achieved the final milestone under a license agreement with an overseas pharmaceutical company for non-clinical and partial clinical trial data, recognizing related revenue in Q1 FY2027.
Source:Aug 13, 2026, 04:26 UTC
Tsubota Laboratory reported its Q1 FY2027 results (April-June 2026) on August 12, 2026, with revenue up 766.7% year-on-year to 215 million yen, and operating, ordinary, and net losses of 170 million, 133 million, and 134 million yen respectively.
Source: